[go: up one dir, main page]

EP2513065B1 - Verfahren zur herstellung von hauptzwischenprodukten zur synthese von rosuvastatin oder pharmazeutisch unbedenklichen salzen davon - Google Patents

Verfahren zur herstellung von hauptzwischenprodukten zur synthese von rosuvastatin oder pharmazeutisch unbedenklichen salzen davon Download PDF

Info

Publication number
EP2513065B1
EP2513065B1 EP10801570.2A EP10801570A EP2513065B1 EP 2513065 B1 EP2513065 B1 EP 2513065B1 EP 10801570 A EP10801570 A EP 10801570A EP 2513065 B1 EP2513065 B1 EP 2513065B1
Authority
EP
European Patent Office
Prior art keywords
rsvltbs
rsvl
rosuvastatin
pharmaceutically acceptable
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP10801570.2A
Other languages
English (en)
French (fr)
Other versions
EP2513065A1 (de
Inventor
Samo Andrensek
Jolanda Anzel
Marjeta Hocevar
Zdenko Casar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals dd filed Critical Lek Pharmaceuticals dd
Priority to EP10801570.2A priority Critical patent/EP2513065B1/de
Publication of EP2513065A1 publication Critical patent/EP2513065A1/de
Application granted granted Critical
Publication of EP2513065B1 publication Critical patent/EP2513065B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Definitions

  • the present invention relates to a process for the preparation of 5-((E)-2-((2S,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonyl amino)pyrimidine (RSVL) as well as a process for preparing crystalline 5-((E)-2-((2S,4R)-4-(tert-butyldimethylsilyloxy)-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine (RSVLTBS) useful as key intermediates for the preparation of rosuvastatin or pharmaceutically acceptable salts thereof.
  • RSVLTBS 5-((E)-2-((2S,4
  • rosuvastatin lactone - RSVL 5-((E)-2-((2S,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine
  • Rosuvastatin calcium is a synthetic lipid-lowering agent that acts as an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase inhibitor).
  • HMG-CoA reductase inhibitors are commonly referred to as "statins.”
  • Statins are therapeutically effective drugs used for reducing low density lipoprotein (LDL) particle concentration in the blood stream of patients at risk for cardiovascular disease.
  • rosuvastatin calcium is used in the treatment of hypercholesterolemia and mixed dyslipidemia.
  • Rosuvastatin and the synthesis of rosuvastatin calcium was first disclosed in EP 521471 A1 ; in the last two steps of the whole synthesis provided by hydrolysis of methyl ester of rosuvastatin (methyl rosuvastatin) in polar solvent, e.g. ethanol, in the presence of a base, following by isolation of sodium salt of rosuvastatin (sodium rosuvastatin) and converting said sodium salt of rosuvastatin with a water soluble calcium salt under aqueous conditions to calcium salt of rosuvastatin.
  • polar solvent e.g. ethanol
  • the object of the present invention is to provide an improved process for preparing 5-((E)-2-((2S,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine (rosuvastatin lactone - RSVL) and a process for preparing crystalline 5-((E)-2-((2S,4R)-4-(tert-butyldimethylsilyloxy)-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine (RSVLTBS), so as to provide valuable intermediates for the preparation of rosuvastatin and pharmaceutically acceptable salts thereof.
  • RSVLTBS 5-
  • the present invention provides the following items including main aspects and preferred embodiments, which respectively alone and in combination particularly contribute to solving the above object and eventually provide additional advantages:
  • rosuvastatin lactone (RSVL)
  • suitable starting material 5-((E)-2-((2S,4R)-4-(tert-butyldimethylsilyloxy)-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine (RSVLTBS) which can be converted to the desired product in a simple manner.
  • RSVLTBS in crystalline form is prepared.
  • RSVLTBS in crystalline form have better thermal stability, and offer advantages for preparing reproducible pharmaceutical formulations compared to amorphous and / or oily substances.
  • RSVLTBS in crystalline form in an aimed and reproducible manner, thereby allowing to obtain RSVLTBS in crystalline form in good purity.
  • the present invention satisfies this need by providing RSVLTBS in crystalline form that is easy to handle and has a high degree of purity and by providing process for repeatedly obtaining said RSVLTBS in crystalline form.
  • desirable key intermediates for the preparation of rosuvastatin or pharmaceutically acceptable salts thereof are provided by a significantly improved process.
  • the compound of formula 5-((E)-2-((2S,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine is prepared by converting 5-((E)-2-((2S,4R)-4-(tert-butyldimethylsilyloxy)-6-oxotetrahydro-2H-pyran-2-yl)vinyl)-4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethanesulfonylamino)pyrimidine (RSVTBLS) by deprotection to compound RSVL as presented on the following scheme:
  • the reaction is performed in the presence of tetrabutylammonium fluoride and acid in organic solvent, preferably said acid is acetic acid and preferably said solvent is tetrahydrofuran.
  • the reaction mixture is heated, preferably to a temperature of about 40 °C and stirred, preferably for a period of 10 to 24 hours, more preferably for a period of 15 to 22 hours.
  • solvent is evaporated and RSVL is isolated (for example as an oily product, preferably RSVL is isolated in a crystalline form).
  • said RSVL (for example isolated as an oily product) can be further purified by extraction.
  • the oily RSVL is dissolved in appropriate solvent, preferably ether is used, most preferably methyl t-butyl ether.
  • the solution is subsequently washed preferably with water and organic solvent is removed, preferably by evaporation and crystalline RSVL can be obtained.
  • Another aspect of present invention is a process for crystallisation of RSVL.
  • Organic solvent is added to RSVL.
  • Said organic solvent is selected from the group consisting of alcohols, ethers and mixtures thereof, more preferably solvent is selected from the group consisting of ethanol, 2-propanol and methyl t-butyl ether, most preferably solvent is 2-propanol.
  • the mixture is subsequently heated to produce clear solution. Crystalline RSVL can be isolated or recovered from the reaction solution by precipitation.
  • the precipitation can be spontaneous depending on solvent system.
  • the precipitation can be induced by reducing the temperature of reaction mixture, especially if initial temperature of reaction mixture is elevated.
  • the precipitation can also be induced by reduction of solution volume, preferably under diminished pressure, or by complete evaporation of solvent.
  • the precipitation may be caused by adding an antisolvent, e.g. water.
  • Said process of crystallisation can be repeated (recrystallisation) in order to further purify RSVL.
  • the precipitation of crystalline RSVL occurs when said heated mixture is left to cool, preferably to room temperature, to give crystals of RSVL. Obtained crystals of RSVL may be separated by techniques well known in the art, e.g.
  • RSVL prepared from RSVLTBS according to the procedure of present invention is crystalline and of high purity (HPLC area % of 97 and higher) and exhibits melting point at about 130 to 145 °C, preferably at about 135 to 141 °C, and might be further characterized by XRD pattern comprising the following characteristic reflection angles at 2 ⁇ values of: 4.0, 7.9, 11.9, 14.7, 15.9, 19.6, 20.2, 21.0, 21.6 and 22.5 respectively exactly or ⁇ 0.2 degrees 2 ⁇ at the indicated 2 ⁇ values.
  • the RSVL prepared from RSVLTBS and further purified either by extraction and/or by crystallisation according to present invention can be obtained in high yields (85 % and higher) and with high purity and is therefore suitable for use in further synthesis steps to obtain rosuvastatin that is less affected by critical byproducts.
  • Amorphous RSVL can be prepared from a solvent selected from the group consisting of dry alcohol (preferably selected form the group consisting of methanol, ethanol and 2-propanol), ester (preferably ethyl acetate and / or methyl t -butyl ether), ether (preferably tetrahydrofuran and / or methyl t -butyl ether) and mixtures thereof.
  • RSVL crystalline or as an oily product
  • RSVL in an amorphous form may be recovered from the solution by spray drying.
  • the RSVL in an amorphous from may be recovered from the solution by freeze-drying.
  • the amorphous form of RSVL can also be recovered from the solution by adding a suitable additional solvent/second solvent resulting in the precipitation of the amorphous form and removing the solvent therefrom by filtration, filtration under vacuum, decantation or centrifugation.
  • amorphous RSVL prepared according to present invention is of high purity and stable enough for the use in the preparation of rosuvastatin or pharmaceutically acceptable salts thereof.
  • RSVLTBS in crystalline form and a process for its preparation.
  • Organic solvent is added to RSVLTBS.
  • Solvent is selected from the group consisting of alkanes, alcohols, ethers, esters and mixtures thereof, preferably in a mixture of an alcohol and an alkane, in which the alcohol is a linear alcohol, preferably a C 2 -C 12 linear alcohol, more preferably a C 2 -C 8 linear alcohol, most preferably n-butanol, and the alkane is preferably C 5 -C 10 linear alkane (n-alkane), more preferably C 6 -C 7 linear alkane is used.
  • the preferred mixture is n-butanol / heptane in a preferred assay of 1 - 50 % (v/v) of n-butanol in C 6 -C 7 linear alkane.
  • RSVLTBS may be dissolved in a solvent or mixture of solvents, optionally the mixture is heated to allow RSVLTBS to dissolve.
  • RSVTBLS is dissolved in more polar phase and then diluted by alkane.
  • the solution is optionally filtered.
  • Crystalline RSVLTBS can be isolated or recovered from the reaction solution by precipitation.
  • the precipitation can be spontaneous depending on solvent system.
  • the precipitation can be induced by reducing the temperature of reaction mixture, especially if initial temperature of reaction mixture is elevated.
  • the precipitation can also be induced by reduction of solution volume, preferably under diminished pressure, or by complete evaporation of solvent.
  • the precipitation may be caused by adding an antisolvent, e.g.
  • the precipitation of crystalline RSVLTBS occurs when said heated mixture is left to cool, preferably to temperature below room temperature, more preferably to temperature below 10 °C, to give crystals of RSVLTBS. Obtained crystals of RSVLTBS may be separated by techniques well known in the art, e.g. filtration, centrifugation, decanting.
  • oily RSVTBLS is dissolved in a mixture of 1 to 20 % n-butanol in C 6 -C 7 linear alkane at temperature around 20 to 30 °C.
  • the mixture is subsequently cooled to a temperature around -20 to +10 °C, preferably to temperature around 0 to 5 °C.
  • crystalline RSVLTBS form I exhibits melting point at about 85 to 105 °C, preferably at about 90 to 100 °C, and might be further characterized by XRD pattern comprising the following characteristic reflection angles at 2 ⁇ values of: 5.1, 10.2, 12.5, 14.7, 15.3, 17.0, 17.7, 20.4, 26.6 and 30.8, respectively exactly or ⁇ 0.2 degrees 2 ⁇ at the indicated 2 ⁇ values (Form I).
  • RSVTBLS is dissolved in a mixture of 10 to 50 % n-butanol in C 6 -C 7 linear alkane by heating, preferably to reflux temperature and than the mixture is cooled to a temperature around -20 to 10 °C, preferably to a temperature below 0 °C.
  • crystalline RSVLTBS form II exhibits melting point at about 70 to 92 °C, preferably at about 78 to 88 °C, and might be further characterized by XRD pattern comprising the following characteristic reflection angles at 2 ⁇ values of: 5.1, 12.4, 13.1, 14.3, 17.6, 18.9, 22.7, 24.2, 24.8 and 25.0, respectively exactly or ⁇ 0.2 degrees 2 ⁇ at the indicated 2 ⁇ values° (Form II)
  • RSVLTBS according to present invention can be isolated as a crystalline material enables efficient purification of RSVLTBS. Isolation of crystalline RSVLTBS results in an enrichment of the main substance and in diminished level of impurities. For example when crystalline form I of RSVLTBS according to present invention is prepared the enrichment from 25 - 40 of HPLC area % to above 60 HPLC area % can be achieved. Furthermore the level of impurities can be significantly reduced ( e.g.
  • the level of RSVLTBS diastereoisomer impurity is reduced to below 20 HPLC area %)
  • the enrichment from 65 HPLC area % to 90 HPLC area % can be achieved and the level of impurities can again be significantly reduced ( e.g. the level of RSVLTBS diastereoisomer impurity can be reduced from 20 HPLC area % to 10 HPLC area % or even lower).
  • the process of crystallisation can be repeated and assays of more than 95 HPLC area % of RSVLTBS and less that 1 HPLC area % of RSVLTBS diastereoisomer impurity may be obtained.
  • purification is performed via crystalline form II of RSVLTBS due to lower solvent volumes used.
  • RSVLTBS one of the most important key intermediates for rosuvastatin synthesis, may contain many impurities (e.g. optical isomers, Z-E isomers as well as cyclic isomer with 8 optical isomers) in different ratios which may consequentially influence the quality of the final rosuvastatin calcium.
  • impurities e.g. optical isomers, Z-E isomers as well as cyclic isomer with 8 optical isomers
  • the RSVLTBS is effectively purified if stationary phase is selected from the group consisting of DIOL and SiO 2 and mobile phase is selected from the group consisting of mixture of n-alkane and alcohol and mixture of n-alkane, alcohol and water.
  • n-alkane is n-hexane or n-heptane and said linear alcohol is preferably C 2 -C 12 linear alcohol, more preferably C 2 -C 8 linear alcohol, most preferably n-butanol is used.
  • RSVLTBS isolated by chromatographic elution was isolated by complete evaporation as an oily substance which may be crystallised according to the invention or by optional concentration and spontaneous precipitation from the eluting solution.
  • Such product is of high purity (preferably having more than 95 HPLC area % of RSVLTBS and having less than 1 HPLC area % of diastereoisomer impurity).
  • crystalline RSVL of high purity (preferably having more than 97 HPLC area % of RSVL) is prepared according to a process comprising the following steps:
  • crystalline RSVL of high purity (preferably having more than 97 HPLC area % of RSVL) is prepared according to a process comprising the following steps:
  • the step b) is omitted and crystalline RSVLTBS is precipitated from mobile phase by cooling to a temperature around -10 to +5 °C.
  • first rosuvastatin or pharmaceutically acceptable salt thereof is provided by the process as described above.
  • rosuvastatin or pharmaceutically acceptable salt thereof is suitably admixed with at least one suitable pharmaceutically acceptable excipient.
  • Pharmaceutically acceptable excipients may be selected from the group consisting of binders, diluents, disintegrating agents, stabilizing agents, preservatives, lubricants, fragrances, flavoring agents, sweeteners and other excipients known in the field of the pharmaceutical technology.
  • excipients may be selected from the group consisting of lactose, microcrystalline cellulose, cellulose derivatives, e.g.
  • hydroxypropylcellulose polyacrylates, calcium carbonate, starch, colloidal silicone dioxide, sodium starch glycolate, talc, magnesium stearate, polyvinylpyrrolidone, polyethylene glycol and other excipients known in the field of the pharmaceutical technology.
  • Crude oil (HPLC: 33.0 % area RSVLTBS) as obtained in Example 1 was diluted in a solvent at 50 °C, which contained 2 vol. % of n -BuOH in n -heptane (20 mg/ml). Milky solution was filtered through 0.2 ⁇ m PTFE (polytetrafluoroethylene) filter and RSVLTBS crystallised from clear, saturated solution by cooling the solution down to 4 °C in darkness. Yield was 50 - 70 %.
  • PTFE polytetrafluoroethylene
  • NP isocratic HPLC-UV preparative chromatography Kromasil 60-5DIOL, 250 x 4.6mm, 10 ⁇ m
  • DIOL stationary phase in the combination with mobile phases constituted from n-hexane and/or n-heptane : alcohols (n 2 - 12) : water in ratios from 99.5 % - 86 % of hexane/heptane : 0.5 % - 14 % of alcohols : 0 -1 % of water (m/m/m) were found to be suitable for preparative RSVLTBS cleaning.
  • the preparative cleaning was performed with linear flow velocities ranged between 3 - 18 cm/min, temperature range 4 - 40 °C, and loadings ranged between 20 - 500 mg of crude RSVLTBS/cm 2 , solvent was 10 to 90 vol.
  • NP isocratic HPLC-UV preparative chromatography Kromasil 100-10SIL; 250 x 4.6mm10 ⁇ m;
  • the preparative purification was performed with linear flow velocities ranged between 3 - 18 cm/min, temperature range 4 - 40 °C, and loadings ranged between 20 - 500 mg of crude RSVLTBS/cm 2 , solvent was 10 to 90 vol. % mixture of ethyl acetate in n-heptane.
  • Crystalline crude RSVL product can be purified by extraction from ether, preferably methyl t-butyl ether.
  • Crystalline crude RSVL product can be further purified by recrystallisation from ethanol, 2-propanol or ethyl acetate:
  • Amorphous RSVL can be prepared from dry alcohol (MeOH, EtOH, i PrOH), ester (AcOEt, t BuOAc) or ether (THF, MTBE) solution of RSVL in Spray Dryer at 70-90 °C in hot nitrogen atmosphere:
  • XRD powder X-ray diffraction
  • the powder X-ray diffraction patterns were obtained by methods known in the art using Philips X'Pert PRO diffractometer with X'Celerator detector using CuK ⁇ radiation (tube operating at 45 kV and 40 mA) in the Bragg-Brentano (reflection) geometry. Data were recorded from 2 to 40 °2 ⁇ in steps of 0.033 °2 ⁇ and the measurement time of 50 seconds per step. Variable divergence and antiscatter slits were used to maintain 12 mm of sample length irradiated.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (10)

  1. Ein Verfahren zum Herstellen der Verbindung der Formel RSVL
    Figure imgb0010
     umfassend die Schritte:
    Bereitstellen einer Verbindung der Formel RSVLTBS:
    Figure imgb0011
     Umwandeln der Verbindung der Formel RSVLTBS in die Verbindung der Formel RSVL durch Entfernung der Silyl-Schutzgruppe und Isolieren der Verbindung der Formel RSVL, wobei das RSVLTBS in kristalliner Form vorliegt.
  2. Das Verfahren gemäß Anspruch 1, wobei der Schritt der Entfernung der Silylschutzgruppe in der Gegenwart von Tetrabutylammoniumfluorid und Säure in organischem Lösungsmittel durchgeführt wird, wobei bevorzugt die Säure Essigsäure ist und wobei bevorzugt das Lösungsmittel Tetrahydrofuran ist.
  3. Das Verfahren gemäß Anspruch 2, wobei das RSVL durch Extraktion mit Ether weiter gereinigt wird, wobei bevorzugt t-Butylether verwendet wird.
  4. Das Verfahren gemäß einem der Ansprüche 2 bis 3, weiter umfassend einen Schritt der Kristallisation von RSVL aus dem aus der aus Alkoholen, Ethern und Mischungen davon bestehenden Gruppe ausgewählten Lösungsmittel, wobei das Lösungsmittel bevorzugt aus der aus Ethanol, 2-Propanol und Methyl-t-butylether bestehenden Gruppe ausgewählt ist.
  5. RSVLTBS in kristalliner Form.
  6. RSVLTBS gemäß Anspruch 5, wobei die kristalline Form aus der aus folgenden bestehenden Gruppe ausgewählt ist:
    a) Form I, gekennzeichnet durch ein Röntgendiffraktometriemuster, welches 6 Peaks bei 2θ-Werten, die aus der aus folgenden bestehenden Gruppe ausgewählt sind, aufweist: 5,1, 10,2, 12,5, 14,7, 15,3, 17,0, 17,7, 20,4, 26,6 und 30,8, jeweils exakt oder ±0.2 Grad in 2θ bei den angeführeten 2θ-Werten,
    und/oder durch
    Aufweisen eines in einen Bereich von 85-105 °C fallenden Schmelzpunkts,
    b) Form II, gekennzeichnet durch ein Röntgendiffraktometriemuster, welches 6 Peaks bei 2θ-Werten, die aus der aus folgenden bestehenden Gruppe ausgewählt sind, aufweist: 5,1, 12,4, 13,1, 14,3, 17,6, 18,9, 22,7, 24,2, 24,8 und 25,0, jeweils exakt oder ±0.2 Grad in 2θ bei den angeführeten 2θ-Werten,
    und/oder durch
    Aufweisen eines in einen Bereich von 70-92 °C fallenden Schmelzpunkts.
  7. Ein Verfahren zur Herstellung von RSVLTBS in kristalliner Form gemäß einem der Ansprüche 5 und 6 umfassend einen Schritt der folgenden:
    a) Hinzugeben von organischem Lösungsmittel zu RSVLTBS, wobei das organische Lösungsmittel eine Mischung aus n-Butanol und n-Heptan oder eine Mischung aus n-Butanol und n-Hexan ist,
    b) optional Erwärmen der Mischung des Schritts a), um es dem RSVLTBS zu ermöglichen, sich zu lösen,
    c) Kühlen der Lösung des Schritts b)
    d) Kristallisierenlassen der Kristalle aus RSVLTB im Anschluss an Schritt c).
  8. Ein Verfahren zur Herstellung von Rosuvastatin oder eines pharmazeutisch akzeptierbaren Salzes davon, umfassend die Schritte:
    a) Ausführen eines Verfahrens zum Herstellen der Verbindung der Formel RSVL gemäß einem der Ansprüche 1 bis 4 und
    b) die so hergestellte Verbindung der Formel RSVL einem weiteren Syntheseschritt unterziehen, um Rosuvastatin oder pharmazeutisch akzeptierbare Salze davon zu erhalten.
  9. Ein Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung umfassend Rosuvastatin als aktiven Inhaltsstoff, umfassend die Schritte:
    a) Herstellen von Rosuvastatin oder pharmazeutisch akzeptierbarer Salze davon gemäß dem Verfahren gemäß Anspruch 8 und
    b) Zumischen des so hergestellten Rosuvastatins oder des pharmazeutisch akzeptierbaren Salzes davon mit zumindest einem pharmazeutisch akzeptierbaren Hilfsstoff.
  10. Verwendung von RSVLTBS gemäß einem der Ansprüche 5 bis 6 für die Synthese von Rosuvastatin oder eines pharmazeutisch akzeptierbaren Salzes davon.
EP10801570.2A 2009-12-16 2010-12-15 Verfahren zur herstellung von hauptzwischenprodukten zur synthese von rosuvastatin oder pharmazeutisch unbedenklichen salzen davon Not-in-force EP2513065B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10801570.2A EP2513065B1 (de) 2009-12-16 2010-12-15 Verfahren zur herstellung von hauptzwischenprodukten zur synthese von rosuvastatin oder pharmazeutisch unbedenklichen salzen davon

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09179416A EP2336116A1 (de) 2009-12-16 2009-12-16 Verfahren zur Herstellung von Hauptzwischenprodukten zur Synthese von Rosuvastatin oder pharmazeutisch unbedenklichen Salzen davon
EP10801570.2A EP2513065B1 (de) 2009-12-16 2010-12-15 Verfahren zur herstellung von hauptzwischenprodukten zur synthese von rosuvastatin oder pharmazeutisch unbedenklichen salzen davon
PCT/EP2010/069706 WO2011073232A1 (en) 2009-12-16 2010-12-15 Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof

Publications (2)

Publication Number Publication Date
EP2513065A1 EP2513065A1 (de) 2012-10-24
EP2513065B1 true EP2513065B1 (de) 2018-10-17

Family

ID=42255122

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09179416A Ceased EP2336116A1 (de) 2009-12-16 2009-12-16 Verfahren zur Herstellung von Hauptzwischenprodukten zur Synthese von Rosuvastatin oder pharmazeutisch unbedenklichen Salzen davon
EP10801570.2A Not-in-force EP2513065B1 (de) 2009-12-16 2010-12-15 Verfahren zur herstellung von hauptzwischenprodukten zur synthese von rosuvastatin oder pharmazeutisch unbedenklichen salzen davon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09179416A Ceased EP2336116A1 (de) 2009-12-16 2009-12-16 Verfahren zur Herstellung von Hauptzwischenprodukten zur Synthese von Rosuvastatin oder pharmazeutisch unbedenklichen Salzen davon

Country Status (4)

Country Link
US (1) US9067895B2 (de)
EP (2) EP2336116A1 (de)
CN (1) CN102753534B (de)
WO (1) WO2011073232A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336116A1 (de) * 2009-12-16 2011-06-22 LEK Pharmaceuticals d.d. Verfahren zur Herstellung von Hauptzwischenprodukten zur Synthese von Rosuvastatin oder pharmazeutisch unbedenklichen Salzen davon
US9850213B2 (en) * 2013-11-25 2017-12-26 Jiangxi Boya Seehot Pharmaceutical Co., Ltd. Method for preparing rosuvastatin sodium

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US7566782B2 (en) 2002-12-10 2009-07-28 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin
WO2005040134A1 (en) 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
US20090124803A1 (en) * 2005-03-22 2009-05-14 Pandurang Balwant Deshpande Process for preparation of rosuvastatin
CN102807530B (zh) * 2005-06-24 2015-08-05 力奇制药公司 制备不含杂质的无定型罗苏伐他汀钙的方法
EP1775299A1 (de) * 2005-10-05 2007-04-18 LEK Pharmaceuticals D.D. Verfahren zur Herstellung von HMG-CoA reduktase Inhibitoren
EP2134696B1 (de) * 2007-04-03 2017-05-17 LEK Pharmaceuticals d.d. Verfahren zur herstellung von statinen, insbesondere von rosuvastatin, und zwischenprodukt für deren herstellung
EP2336116A1 (de) * 2009-12-16 2011-06-22 LEK Pharmaceuticals d.d. Verfahren zur Herstellung von Hauptzwischenprodukten zur Synthese von Rosuvastatin oder pharmazeutisch unbedenklichen Salzen davon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
US9067895B2 (en) 2015-06-30
US20130018065A1 (en) 2013-01-17
CN102753534A (zh) 2012-10-24
WO2011073232A1 (en) 2011-06-23
EP2336116A1 (de) 2011-06-22
EP2513065A1 (de) 2012-10-24
CN102753534B (zh) 2015-09-02

Similar Documents

Publication Publication Date Title
EP1682536B1 (de) Verfahren zur herstellung des calciumsalzes von rosuvastatin-(e)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-ensäure- und kristallinen zwischenprodukten davon
AU762909B2 (en) Crystalline bis((E)-7- ( 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino) pyrimidin -5-yl) (3R,5S)-3, 5-dihydroxyhept -6-enoic acid]calcium salt
EP1663989B1 (de) Kristalline form von bis[(e)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-ensäure]-calciumsalz
EP2752407B1 (de) Kristallines Rosuvastatin Calzium-Trihydrat
AU2004274239A1 (en) Polymorphic forms of a known antihyperlipemic agent
EP2513065B1 (de) Verfahren zur herstellung von hauptzwischenprodukten zur synthese von rosuvastatin oder pharmazeutisch unbedenklichen salzen davon
HK1092462B (en) Process for the manufacture of the calcium salt of rosuvastatin (e)-7-[4- (4-fluorophenyl) -6-isopropyl-2-[methyl(methylsulfonyl) amino]pyrimidin -5-yl] (3r, 5s) -3, 5-dihydroxyhept-6-enoic acid and crystalline intermediates thereof
HK1152042A (en) Process for the manufacture of the calcium salt of rosuvastatin and crystalline intermediates thereof
HK1090361B (en) Crystalline form of bis (e)-7- 4-(4-fluorophenyl)-6-isopropyl-2-methyl(methylsulfonyl)amino pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoicacid calcium salt

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120712

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20161207

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20180522

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010054455

Country of ref document: DE

Ref country code: AT

Ref legal event code: REF

Ref document number: 1053856

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181115

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20181017

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1053856

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190217

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190117

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190217

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190118

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010054455

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181215

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

26N No opposition filed

Effective date: 20190718

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181215

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181017

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181017

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20101215

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20211125

Year of fee payment: 12

Ref country code: GB

Payment date: 20211118

Year of fee payment: 12

Ref country code: DE

Payment date: 20211116

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602010054455

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20221215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221215

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231